Biotech News

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

AxoGen (AXGN)AxoGen2026-06-25 13:46 ESTPartnership

December 17, 2025 7:00am EST

ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference.

Axogen’s management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at ir.axogeninc.com .

About Axogen

Axogen (NASDAQ: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.​

For more information, visit www.axogeninc.com .

Contact: Axogen, Inc. InvestorRelations@axogeninc.com

Source: Axogen, Inc. Released December 17, 2025

Open original release

Related news

AxoGen

AxoGen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
39.49 USD
Market cap
2.16B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States